Health ConditionsHealthy weight is most commonly defined in clinical and public health contexts using the Body Mass Index (BMI), a mathematical ratio of body weight in kilograms to the square of height in metres (kg/m²). A healthy weight for adults is generally defined as a BMI between 18.5 and 24.9. In 1998, an NIH report concluded that a BMI over 25 is overweight and a BMI over 30 is obese; in the 1990s, the World Health Organization (WHO) adopted the same thresholds, deciding that a BMI of 25 to 30 should be considered overweight and a BMI over 30 obese.
BMI is widely used as a screening tool, but its limitations are well recognised. The National Institutes of Health (NIH) in the United States published guidelines in 1998 that are still promoted by the Centers for Disease Control and Prevention (CDC), recommending the use of BMI as a practical approach in the clinical setting, though both NIH and similar bodies warn that BMI does not provide a direct measure of adiposity. BMI is used as an index of a healthy body weight, but it assumes a normal distribution between muscular and adipose tissue and would not be appropriate for muscular individuals such as athletes.
Ethnic variation also affects the utility of standard BMI cut-offs. In South East Asian and South Chinese populations, adjusted BMI Prime should be calculated using an upper limit BMI of 23 rather than 25. More broadly, BMI is influenced by factors such as age, sex, ethnicity, muscle mass, body fat, and activity level, among others.
Defining healthy weight solely by BMI misses important distinctions in body composition and metabolic status. The BMI category of normal body weight includes, in addition to people with normal body composition, people with both deficient and excess body components, such as excess body fat or deficient lean body mass.
Too little or too much body fat in underweight and overweight/obese individuals reflects a risk of disease predisposition. A healthy metabolism is maintained through normal homeostasis and appropriate regulation of blood pressure, blood glucose, and lipid profiles.
The concept of metabolically healthy obesity (MHO) further complicates simple weight-based definitions. Metabolically healthy obesity refers to an obesity phenotype with no or little evidence of metabolic dysfunction; lower liver fat content and visceral adipose tissue, greater insulin sensitivity and secretion, greater cardiorespiratory fitness, and predominantly lower-body fat deposition are key physiological traits of a metabolically healthy phenotype. Conversely, not all lean subjects are necessarily free of metabolic risk factors. Characteristics of metabolically unhealthy normal weight (MUNW) include excess abdominal subcutaneous and visceral fat, fat deposits in organs and muscle tissue, reduced skeletal muscle mass, low cardiorespiratory fitness, adipose tissue inflammation, and higher levels of inflammatory markers.
However, long-term evidence cautions against viewing "metabolically healthy" obesity as a stable state. Apparently metabolically healthy subjects with obesity may be in transition to a clearly unhealthy phenotype following longer "incubation time," further fat mass expansion, and/or aging. Recent evidence indicates that even presumably healthy obesity is linked to increased long-term morbidity and mortality.
Maintaining a healthy weight supports the cardiovascular (heart), kidney, and metabolic systems — the way the body creates, stores, and uses energy. Together, this is called cardiovascular-kidney-metabolic health (CKM health).
At the metabolic level, healthy weight is associated with well-regulated glucose homeostasis. Research frequently identifies a dose-response relationship, where increasing BMI categories correlate with progressively higher mean HOMA-IR (homeostatic model assessment of insulin resistance) values, indicating a continuous deterioration of insulin sensitivity as body weight increases.
Weight loss is associated with metabolic changes mostly favourable to improving the overall health of an individual. A direct link is shown between weight loss and improvement in metabolic diseases such as hypertension, blood glucose, lipid profiles, sleep apnea, and comorbidities such as non-alcoholic fatty liver disease, polycystic ovarian syndrome, infertility, and type 2 diabetes. Even modest reductions in weight from an unhealthy range carry measurable benefit: at the metabolic level, weight loss of 5% of initial weight is associated with improvement in biochemical and physiological parameters of the body and thus health benefits.
The gut microbiome is increasingly recognised as a system involved in weight regulation. Emerging evidence suggests a close connection between the gut microbiome and both human obesity and dyslipidemia, suggesting that the gut microbiome may play an important role in the obesity-dyslipidemia relationship. Studies have shown that visceral fat area (VFA) is more related to the intestinal microbiome than BMI and waist circumference. Research in Mediterranean diet cohorts has further demonstrated that the Mediterranean diet has a beneficial effect on metabolic and chronic diseases, including obesity, partly through beneficial changes in gut microbiota composition and function; a high proportion of plant-based foods correlates with a higher percentage of short-chain fatty acids (SCFAs) and fibre-degrading bacteria in the faeces.
Weight is affected by many factors. Genetics, hormones, environment, medications, and stress all play a significant role. Hormonal signals including leptin, ghrelin, adiponectin, and insulin are closely tied to energy homeostasis, appetite regulation, and fat storage patterns, as evidenced in clinical trials studying green tea extract mechanisms (discussed below).
The distribution of fat is as relevant as total body weight. Abdominal obesity is known to significantly increase the risk of metabolic syndrome and cardiovascular disease. Several clinical indicators are significantly higher in people with high visceral fat area compared with those with low visceral fat area, including waist circumference, fasting blood glucose, triglycerides, total cholesterol, LDL cholesterol, and serum uric acid.
Mental stress, in or not in association with impaired sleep, may play a role in poor sleep, enhanced appetite, cravings, and decreased motivation for physical activity — all of which contribute to weight gain and obesity, possibly by decreasing the efficacy of weight loss interventions. Sleep disruption increases stress by triggering the hypothalamic-pituitary-adrenal (HPA) axis and dysregulating the production of cortisol; in turn, stress increases sleep disruption.
Sleep hygiene and circadian rhythmicity are proven to impact cortisol profiles through a decreased efficacy of the negative-feedback regulation of the HPA axis. Poor sleep quality is independently associated with weight-related metabolic disruption. Physical activity has been shown to decrease cortisol levels and improve sleep outcomes in adults.
The Mediterranean dietary pattern is among the most extensively studied dietary approaches in relation to weight and metabolic health. It is characterised by a high intake of vegetables, fruits, nuts, cereals, whole grains, and extra-virgin olive oil, as well as a moderate consumption of fish and poultry, and a limited intake of sweets, red meat, and dairy products; adherence is characterised by high intake of monounsaturated fat and fibre, and low saturated fat, with a balanced ratio of omega-6 to omega-3 essential fatty acids.
Regarding weight loss maintenance, results from the MedWeight study (n = 565 adults) suggest that high adherence to the Mediterranean diet is associated with a two-fold increased likelihood of weight loss maintenance, an association attributed mainly to the Mediterranean diet as a whole dietary pattern.
A 2016 systematic review of RCTs (published in The American Journal of Medicine) examining the Mediterranean diet for long-term weight loss noted it searched MEDLINE, EMBASE, and the Cochrane Library for RCTs with follow-up ≥12 months in overweight or obese individuals; five RCTs (n = 998) met inclusion criteria. The authors noted that with heterogeneity in design, population, and comparator, statistical pooling was not possible, and this finding highlights the dearth of rigorous trials in this area; with 89.9% of included participants having established cardiovascular disease or type 2 diabetes, generalisability to the general population of overweight or obese individuals is unclear.
Higher dietary protein intake is supported by clinical evidence as an aid to weight management through multiple mechanisms. Available evidence suggests that meals and diets containing higher protein content elicit higher energy expenditure than those containing less protein. Improvements in satiety, glycaemic control, and cardiometabolic risk factors have been reported with higher protein diets.
A 12-week, randomised, double-blind, placebo-controlled trial (n = 206 overweight/obese adults) compared a high-protein and fibre-based shake (17 g protein, 6 g fibre) with an isocaloric low-protein, lower-fibre placebo taken twice daily before meals, alongside a 500 kcal/day deficit. Healthy overweight and obese adults (BMI 27–35; 70% female) were randomly assigned; primary outcomes included body weight and total body fat percentage. The study authors noted that it has been hypothesised that protein sources with higher levels of branched-chain amino acids may elicit stronger satiety responses, but additional research is needed due to conflicting evidence.
Dietary fibre — particularly soluble fibre — has a well-supported role in weight management through satiety mechanisms. Evidence has shown that soluble dietary fibre slows gastric emptying, increases perceived satiety, and plays a significant role in appetite regulation. These fibres are essential for maintaining digestive health, as they aid in promoting regular bowel movements and fostering a balanced gut microbiome; furthermore, they can help manage blood sugar levels, reduce cholesterol, and enhance satiety, which may support effective weight control.
A 2019 systematic review and meta-analysis of RCTs examining soluble dietary fibre and satiety in healthy adults found that meta-analysis of pooled data showed that guar gum had the largest effect on post-meal energy intake, followed by β-glucan, alginate, polydextrose, and pectin. The authors noted that the risk of bias was high for each study as assessed using the Jadad scale, limiting the strength of conclusions.
A 2022 PMC narrative review on protein, fibre, and exercise found that results from several meta-analyses of RCTs have demonstrated that interventions involving various types and doses of dietary fibre improve cardiometabolic risk factors, with a meta-analysis examining soluble fibre showing greater reductions in total cholesterol, LDL-C, non-HDL-C, apoB, and triglyceride levels compared to control interventions.
A review of 12 systematic reviews and meta-analyses encompassing 149 controlled trials on exercise training in adults with overweight or obesity found that exercise training — whether aerobic activity alone, muscle-strengthening alone, or a combination — resulted in significantly greater weight loss (mean differences ranging from −1.5 to −3.5 kg), total fat loss (−1.3 to −2.6 kg), and visceral fat loss (−0.3 to −0.6 kg), compared to control conditions.
Traditional Use: Camellia sinensis (green tea) has been consumed in East Asian cultures for millennia, particularly in China, Japan, and Korea, both as a daily beverage and as a remedy for a variety of conditions. Traditional Chinese medicine recognised green tea as an aid to digestion and for "removing phlegm" (clearing metabolic excess). It was not traditionally used in isolation as an extract, but consumed as brewed leaf tea. The concept of using concentrated EGCG for weight management is a modern formulation, not a classical herbal practice.
Scientific Evidence: A meta-analysis examining nine clinical trials involving 532 participants found a moderate effect size (Cohen's d: −0.74, 95% CI: −1.40, −0.08; P = 0.03, I² = 0.92), suggesting the potential for weight reduction through green tea extract (GTE) use; however, some clinical trials have conflicting opinions regarding effectiveness, and while the results demonstrate that GTE consumption may assist in weight control with significant statistical findings, it may not be clinically significant. The substantial heterogeneity among the included studies (I² = 92%) underscores the need for further research to standardise interventions and yield more conclusive evidence.
A randomised, double-blind, placebo-controlled trial in 102 women with central obesity tested high-dose EGCG (856.8 mg/day) for 12 weeks. Significant weight loss (from 76.8 ± 11.3 kg to 75.7 ± 11.5 kg; p = 0.025), as well as decreases in BMI (p = 0.018) and waist circumference (p = 0.023) were observed in the treatment group, with a consistent trend of decreased total cholesterol reaching 5.33% and decreased LDL plasma levels. Significantly lower ghrelin levels and elevated adiponectin levels were detected in the study group compared with the placebo group.
By contrast, an earlier RCT reported that there was no statistical difference in percentage reduction in body weight, BMI, or waist circumference between the GTE group (491 mg catechins containing 302 mg EGCG) and placebo group after 12 weeks of treatment, though the intake was considered safe.
Evidence assessment: The evidence for EGCG/green tea extract on weight is mixed. Results are highly heterogeneous across trials, effect sizes are small to moderate, and clinical meaningfulness is uncertain. Dose, preparation form, and population characteristics appear to strongly influence outcomes. The evidence is preliminary and insufficient to establish definitive clinical recommendations.
Traditional Use: Glucomannan is derived from the tuber of Amorphophallus konjac, a plant native to East and Southeast Asia. The konjac tuber has been used in traditional Japanese and Chinese culinary and folk medicine for centuries, consumed as a gelatinous food (konnyaku or shirataki noodles) valued for its bulk-forming, digestive, and satiety properties. Its traditional use centred on food rather than isolated supplementation.
Scientific Evidence: Glucomannan is a water-soluble, fermentable dietary fibre extracted from the tuber of Amorphophallus konjac; it consists of a polysaccharide chain of beta-D-glucose and beta-D-mannose, and because human salivary and pancreatic amylase cannot split its beta-1,4 linkages, glucomannan passes relatively unchanged into the colon, where it is highly fermented by colonic bacteria.
Mechanistically, konjac glucomannan (KGM), which hydrates gradually and develops high viscosity in solution, has the highest hydrated volume at the lowest concentration of any dietary fibre; oral KGM can instil a feeling of fullness at a lower dose than other fibre supplements through increasing gastric retention and delaying gastric emptying via a gel-like viscous mass that triggers afferent vagal signals of fullness, while absorption of nutrients in the lumen is slowed and appetite-related hormones are increased.
A 2025 systematic review and meta-analysis of 10 RCTs (2014–2024) found that KGM supplementation of ≥5 g/day for ≥12 weeks is frequently associated with reductions in BMI (mean: 1.49 kg/m²), weight (mean: 3.18 kg), and waist circumference (mean: 2.11 cm) in overweight and obese individuals. A 2014 systematic review searching Medline, Embase, AMED, and the Cochrane Library specifically included only RCTs in overweight or obese participants, using body weight and BMI as primary outcomes. The increased prevalence of obesity has resulted in high popularity of dietary supplements marketed as weight-reducing agents; the efficacy of most such supplements is not established, though glucomannan is often recommended for weight loss.
Evidence assessment: The body of evidence for glucomannan suggests a modest but consistent effect on body weight in overweight/obese individuals when used at doses ≥5 g/day for ≥12 weeks. Effect sizes are clinically modest, many trials are short-term and small, and there is variability in quality. The mechanism — viscosity-driven gastric distension and delayed absorption — is biologically plausible and supported by both mechanistic data and clinical trials. The evidence is graded as moderate.
Traditional Use: Omega-3-rich foods — particularly fatty fish, fish liver oils, and marine mammals — have long formed dietary staples in Nordic, Inuit, Japanese coastal, and Mediterranean cultures. Fish and fish oils were used in folk and traditional medicine primarily for joint complaints and general vitality, not specifically for weight management. The association with weight and metabolic health has emerged from modern epidemiological and interventional research.
Scientific Evidence: A 2021 systematic review and meta-analysis of RCTs examined the effect of omega-3 supplementation on metabolic and inflammatory biomarkers in patients with type 2 diabetes. Data abstracted included first author name, year, number of participants in omega-3 and control groups, dose of omega-3 supplement, and treatment duration; systematic assessment of bias was performed using the Cochrane criteria. Regarding body weight specifically, a 2022 narrative review concluded that a higher protein diet achieved with the substitution of protein for carbohydrates, especially added sugars and refined starches, improves the cardiometabolic risk factor profile — a finding relevant to dietary patterns that are naturally high in omega-3s.
The role of omega-3 fatty acids in the context of metabolic weight health is primarily through their anti-inflammatory properties and their effects on lipid parameters rather than direct body weight reduction per se. Adherence to the Mediterranean dietary pattern is characterised by a balanced ratio of omega-6/omega-3 essential fatty acids, and this balance is considered one of its key metabolically protective features.
Evidence assessment: The evidence for omega-3 supplementation as a primary agent for reducing body weight is weak; its more robust role is in metabolic health outcomes (triglycerides, inflammation, insulin sensitivity) that accompany healthy weight. It should be understood in the context of overall dietary quality rather than isolated supplementation for weight reduction.
Traditional Use: High-protein foods (legumes, fish, game meat, eggs, dairy) have formed the dietary foundation of most traditional cultures. Their satiating properties were implicitly recognised across cultures without attribution to a specific mechanism.
Scientific Evidence: The thermogenic effect of protein is well documented. A systematic review and meta-analysis of 52 RCTs investigating the impact of acute meals and longer-term diets containing different amounts of protein on energy expenditure found that meals and diets containing higher protein content elicit higher energy expenditure than those containing less protein; in acute studies, consuming higher versus lower protein meals yielded greater diet-induced thermogenesis.
Regarding protein source, a meta-analysis that examined the effects of various protein sources on diet-induced thermogenesis and resting energy expenditure found no differences between different protein sources — including both animal and plant proteins — on these energy expenditure parameters. At the level of satiety signalling, an RCT found that, compared with soy protein, micellar casein and pea protein isolates consumed for three days reduced post-prandial appetite scores and increased satiety signals, whereas whey protein did not; however, the source of protein had no effect on subsequent energy intake either immediately after or four hours after the protein preload.
Evidence assessment: Evidence for higher dietary protein supporting weight management through increased satiety and thermogenesis is strong and consistent across multiple systematic reviews and meta-analyses of RCTs. The practical relevance is for dietary protein distribution throughout the day rather than isolated supplementation.
Traditional Use: High-fibre diets based on whole grains, legumes, fruits, and vegetables have characterised traditional diets globally for millennia. Psyllium husk (Plantago ovata) was used in Ayurvedic medicine as a digestive and laxative agent; oat bran (β-glucan source) featured prominently in Northern European traditional diets. The satiety-promoting and "filling" nature of fibre-rich foods has been long recognised in culinary traditions.
Scientific Evidence: Evidence has shown that soluble dietary fibre slows gastric emptying, increases perceived satiety, and plays a significant role in appetite regulation. A 2019 systematic review and meta-analysis of RCTs found differential effects depending on fibre type. A recent systematic review and meta-analysis reported greater reductions in BMI, body weight, and body fat, and greater improvements in cardiometabolic outcomes with the consumption of soluble fibre compared with placebo.
Animal model evidence provides mechanistic insight: sustained intake of three different soluble dietary fibres decreased food intake, weight gain, and adiposity, increased circulating satiety hormones GLP-1 and PYY, and increased hindgut fermentation in a rat model. However, data from human trials remain equivocal.
Evidence assessment: The evidence for soluble dietary fibre supporting weight management via satiety modulation is moderate in strength. Human RCTs show variable effect sizes depending on fibre type, dose, and study design quality. The most consistent evidence is for viscous fibres (guar gum, β-glucan, psyllium, glucomannan). High risk-of-bias ratings in many trials limit definitive conclusions.
Following a heart-healthy eating plan and being physically active are recognised ways to help achieve and maintain a healthy weight. The evidence from large-scale reviews is robust: a review of 12 systematic reviews and meta-analyses encompassing 149 controlled trials found that exercise training resulted in significantly greater weight loss (mean differences −1.5 to −3.5 kg), total fat loss (−1.3 to −2.6 kg), and visceral fat loss (−0.3 to −0.6 kg) compared with control conditions.
Managing stress and having good-quality sleep are inter-related factors essential for health, and both factors are affected by physical activity; there is an established bidirectional relationship between stress and sleep. Sleep disruption is directly linked to hormonal dysregulation relevant to weight: sleep disruption increases stress by triggering the HPA axis and dysregulating the production of cortisol.
Mental stress — in or not in association with impaired sleep — may promote poor sleep, enhanced appetite, cravings, and decreased motivation for physical activity, and all these factors contribute to weight gain and obesity, possibly via decreasing the efficacy of weight loss interventions.
What the evidence underlines is the importance of basing one's diet on whole, nutrient-dense foods; getting plenty of exercise; managing metabolic risk factors including insulin sensitivity and visceral fat levels; and prioritising supportive lifestyle habits such as stress management and adequate sleep. No single food or supplement has been shown to replicate the magnitude of benefit conferred by a coherent, whole-diet approach. A more holistic approach to metabolic health considers multiple factors beyond weight, including body composition, lifestyle habits, and metabolic syndrome criteria, advocating for a focus on whole foods and active living.
5-HTP raises brain serotonin, which suppresses appetite and reduces carbohydrate intake. Multiple double-blind RCTs in overweight and obese subjects found significant reductions in caloric intake and body weight at doses of 600–900 mg/day over 8–12 weeks. A 2023 study also found reductions in fat mass at 100 mg/day for 8 weeks.
7-Keto-DHEA is a naturally occurring, non-hormonal metabolite of DHEA that acts as a thermogenic agent by upregulating hepatic thermogenic enzymes (including those involved in fatty acid oxidation) without androgenic or estrogenic activity. A 2022 systematic review of 4 RCTs found 2 showed significant body weight reduction, 1 decreased body fat percentage, and 2 showed increased resting metabolic rate.
Several RCTs report that acacia gum supplementation reduces BMI and body fat percentage in overweight adults and diabetic patients. A 12-week RCT in type 2 diabetic patients found significant reductions in BMI (2%) and visceral adiposity index (23.7%). A separate RCT in adults at risk of metabolic syndrome reported decreased fat-free body mass and carbohydrate intake.
Multiple animal studies demonstrate that whole adzuki bean and its water extracts reduce body weight, adipose tissue accumulation, and fat vacuole formation in high-fat diet models. The bean has been used for weight control in China since the Tang Dynasty. Human clinical evidence is limited but the animal data are consistent.
The Maeda et al. (2005) RCT demonstrated significantly greater body weight loss (−2.8 kg vs. −1.3 kg) and BMI reduction (−1.1 vs. −0.5 kg/m²) in the agar group versus conventional diet over 12 weeks, alongside reductions in visceral fat, subcutaneous fat, and total body fat measured by DXA and CT. This is the strongest human evidence for agar's role in weight management.
Akkermansia muciniphila is a gut bacterium that strengthens the intestinal mucus barrier and is inversely associated with obesity and metabolic disorders. A landmark 2019 double-blind RCT found pasteurized A. muciniphila supplementation in overweight/obese adults significantly reduced fat mass, plasma insulin, and improved metabolic risk factors versus placebo over 3 months.
Multiple systematic reviews and meta-analyses of RCTs confirm ALA supplementation produces statistically significant but modest reductions in body weight and BMI. A 2017 meta-analysis of 12 RCTs reported −0.69 kg weight and −0.38 kg/m² BMI reduction versus placebo. A 2020 dose-response meta-analysis confirmed these findings without departure from linearity.
Alginate supplementation as an adjunct to energy restriction has been shown in at least one well-designed RCT to improve weight loss in obese subjects. Additional mechanisms include inhibition of pancreatic lipase and modulation of gut microbiota linked to obesity-related metabolism. Evidence across longer-term trials is limited but promising.
Despite being calorie-dense, consistent RCT and meta-analytic evidence shows that including almonds in the diet does not cause weight gain and may support weight management by enhancing satiety, reducing energy intake at subsequent meals, and increasing resting energy expenditure. Meta-analyses suggest modest reductions in body weight and waist circumference.
Anchovies are high in protein and low in calories, supporting satiety and lean mass preservation that facilitates healthy weight management. Protein has well-established effects on appetite suppression via reduction of ghrelin. DHA and EPA have also been studied in the context of body composition in caloric-restriction settings.
Epidemiological studies consistently associate whole apple consumption with lower body weight and BMI. RCTs show that substituting whole apples for processed snacks reduces caloric intake, and apple polyphenols may modestly influence fat metabolism, though interventional evidence on weight as a primary outcome is limited.
Apple cider vinegar's acetic acid content slows gastric emptying, reduces postprandial glucose and insulin, and promotes satiety, contributing to reduced caloric intake and modest weight loss. A 12-week double-blind RCT in 175 obese Japanese subjects found daily consumption of 1–2 tablespoons significantly reduced body weight, BMI, visceral fat, and waist circumference versus placebo.
Artichoke (Cynara scolymus) leaf extract contains cynarin and chlorogenic acid that stimulate bile secretion to improve fat digestion and inhibit cholesterol synthesis. Clinical evidence shows artichoke extract significantly reduces LDL cholesterol, improves liver function, and modulates lipid metabolism, with mechanistic support for weight management through bile acid and lipid regulation.
Several animal studies show ashitaba extract suppresses diet-induced obesity via AMPK activation and reduced lipogenesis. Two small human RCTs (8 weeks, 200 mg/day chalcone powder) assessed visceral fat and body composition in overweight adults. Results were pilot-level and require confirmation in larger trials.
Meta-analysis of RCTs found astaxanthin did not significantly affect BMI (SMD: −0.02; p=0.821), and most individual trials show no meaningful weight reduction. However, in obesity models and some human trials, ASX reduces adipose tissue inflammation and improves metabolic markers such as insulin sensitivity and lipid profiles that accompany weight-related conditions.
Oral ATP disodium supplementation combined with resistance training has been shown in an RCT to produce significantly greater gains in lean body mass compared to exercise alone. A systematic review and meta-analysis confirmed that 400 mg/day ATP supplementation in resistance-trained men significantly improved maximal strength and lean mass. These effects are attributed to enhanced muscle protein accretion and reduced muscle breakdown rather than fat loss per se.
Multiple preclinical studies demonstrate anti-obesity activity of Atractylodes macrocephala extracts, including reduction of body weight, adipose tissue, and serum lipids in high-fat-diet mouse and rat models. Mechanisms include inhibition of adipogenesis, enhanced energy metabolism via AMPK/PGC1α, and modulation of intestinal microbiota.
Bamboo shoot fiber has demonstrated significant anti-obesity effects in multiple rodent studies, reducing body weight by up to 30.56% in high-fat-diet models. It reduces fat accumulation, improves dyslipidemia and insulin resistance, and does so partly through modulation of the gut microbiome. In TCM, bamboo shoots are used to promote weight management.
Banaba (Lagerstroemia speciosa) leaves contain corosolic acid and lagerstroemin, which activate insulin-like glucose uptake and reduce postprandial glucose, indirectly supporting weight management by reducing excess glucose available for fat storage. Clinical studies show significant reductions in blood glucose and body weight in subjects with glucose metabolism disorders.
Native banana starch supplementation at 24 g/day for 4 weeks significantly reduced body weight in obese type 2 diabetic women in a controlled trial. Green banana products are also associated with weight control benefits in the 2019 systematic review of 18 studies. Banana's resistant starch and soluble fiber increase satiety and slow gastric emptying.
Human evidence suggests baobab's high fiber content may support weight management via appetite suppression. A clinical trial (n=20) found that 15 g of baobab extract in a smoothie significantly reduced subjective hunger compared with placebo. Baobab's fiber also slows gastric emptying and blunts postprandial glucose spikes, both of which are associated with reduced caloric intake. Evidence for direct body weight reduction from baobab supplementation in human trials is not yet established.
Berberine from barberry has demonstrated modest weight-loss effects in human studies, with pilot data showing approximately 5 lb average weight loss in obese subjects over 12 weeks and significant waist circumference reductions in meta-analyses of RCTs. AMPK activation inhibiting adipogenesis is the main mechanism.
Barley β-glucan reduces energy intake by promoting satiety and delaying gastric emptying. Clinical trials show reductions in BMI and waist circumference with barley β-glucan consumption, and animal evidence supports body fat reduction. Human evidence for meaningful weight loss per se is modest.
Beef protein supplementation significantly increases lean body mass and reduces fat mass in exercising individuals, contributing to improved body composition. High dietary protein generally promotes satiety and thermogenesis, with beef protein studied as a specific source leveraging these effects.
Berberine, an alkaloid from plants including Berberis and Coptis, activates AMPK and inhibits PCSK9, reducing body weight and waist circumference in clinical trials. A 2020 meta-analysis of 12 RCTs found berberine significantly decreased body weight (−2.07 kg), BMI, and waist circumference versus placebo. It also improves insulin sensitivity, supporting metabolic weight management.
Beta-glucan may support healthy weight through satiety enhancement, blunted postprandial glucose-insulin responses, and favorable effects on gut microbiota composition. Clinical trial evidence for direct body weight reduction is modest and mixed, with the most consistent findings around viscosity-dependent suppression of appetite. It is being investigated as an adjunct to caloric restriction.
A 2019 meta-analysis of six RCTs found betaine supplementation significantly reduced body fat mass and body fat percentage, though not total body weight or BMI. Effects appear most pronounced when combined with resistance training. A 2021 meta-analysis reached conflicting conclusions, finding no significant improvement in fat mass or fat-free mass, highlighting the evidence remains contested.
B. animalis subsp. lactis BB-12 has been evaluated for anti-obesity effects in animal models, showing gut microbiota regulation in human microbiota-associated rats. B. animalis CECT 8145 reduced anthropometric adiposity biomarkers in a clinical RCT in abdominally obese subjects. B. animalis TA-1 combined with L. paracasei also produced significant reductions in body weight and BMI in metabolic syndrome subjects over 12 weeks.
Multiple RCTs have demonstrated that B. breve B-3 significantly reduces body fat mass, body weight, and waist circumference in overweight and pre-obese adults. A 12-week RCT in pre-obese adults found significantly lower body fat mass and percent body fat compared to placebo. These findings have been replicated in a separate RCT in Korean adults with overweight.
B. lactis HN019 significantly reduced BMI in a randomized trial in metabolic syndrome patients. Broader evidence from Bifidobacterium meta-analyses supports modest effects on adiposity in obese or metabolically compromised individuals, linked to shifts in gut microbiota composition and SCFA-mediated energy regulation.
Bile acid signaling via TGR5 promotes energy expenditure by stimulating thyroid hormone (T3) production in brown adipose tissue and muscle. Bariatric surgery—associated with doubled serum bile acid concentrations—produces significant weight loss, and the bile acid component of the hormonal response is considered a contributing factor. Bile acid pool composition differs between obese and normal-weight individuals.
A 2025 meta-analysis of 82 RCTs found N. sativa supplementation significantly improved BMI, body fat percentage, waist circumference, weight, and waist-to-hip ratio. A 2025 PubMed study confirmed anti-adipogenic and lipid-lowering effects of N. sativa in human subjects.
Piperine inhibits adipogenesis (new fat cell formation), activates thermogenesis via catecholamine release, and may modestly reduce appetite. Multiple animal studies document reductions in body fat. Human evidence is preliminary and mostly indirect via metabolic syndrome RCTs reporting reduced waist circumference and weight alongside lipid improvements.
Black tea polyphenols modulate gut microbiota in ways associated with reduced fat deposition, and caffeine contributes modest thermogenic and fat-oxidation effects. Animal studies show black tea suppresses body weight gain on high-fat diets via GLUT4 and AMPK pathway mechanisms. Human clinical evidence for weight loss specifically from black tea is modest.
Human clinical trials using a bladderwrack-rockweed combination product (Gdue) demonstrated significant reductions in waist circumference and metabolic syndrome markers over 6 months. Animal studies show fucoidan prevents weight gain on high-fat diets. Thyroid-mediated metabolism support via iodine is the traditional primary mechanism.
Sulforaphane has been shown to reduce fat mass in human studies and animal models. A systematic review of cardiometabolic trials found that broccoli sprout supplementation produced marginally significant changes in body weight and fat markers, consistent with sulforaphane's known effect on adipogenesis and metabolic pathways.
A 2021 systematic review and meta-analysis of 13 RCTs (Critical Reviews in Food Science and Nutrition) found brown rice significantly reduced body weight (−1.63 kg), BMI (−0.58 kg/m²), and waist circumference (−2.56 cm) vs. white rice. Pre-germinated brown rice produced even larger reductions. The 2013 Nutrition Journal RCT also found rice protein isolate equivalent to whey in reducing fat mass while increasing lean body mass.
Brussels sprouts are low in calories (~40 kcal/cup raw), high in fiber (3–4 g/cup), and have a high water content — a nutrient profile associated with satiety, reduced caloric density, and support for weight management. High-fiber diets are scientifically recognized to promote healthy body weight.
Tributyrin prevented body weight gain and reduced adipose tissue inflammation in obese high-fat-diet mice. A sodium butyrate RCT in humans with obesity showed reductions in weight and BMI over 8 weeks. However, the Frontiers in Pharmacology (2021) review concluded no RCT has confirmed an anti-obesity effect of butyrate specifically, and evidence in humans remains limited and inconsistent.
Animal evidence strongly supports butyrate preventing diet-induced obesity via increased energy expenditure and mitochondrial function. Human evidence is emerging, with a 2026 RCT targeting weight loss with oral sodium butyrate in overweight/obese adults. Lower butyrate is consistently observed in obese individuals.
Caffeine is a well-established thermogenic and lipolytic agent that increases resting metabolic rate and fat oxidation. The NIH ODS recognizes caffeine as one of few weight-loss supplement ingredients with credible evidence. Meta-analyses confirm modest but significant reductions in body weight, particularly when combined with other ingredients like green tea catechins.
In a 2019 Gut study, camu camu extract prevented weight gain in high-fat-diet mice by increasing energy expenditure and altering gut microbiota. A 2022 dose-ranging mouse study also showed camu camu reduced obesity-related parameters. A human trial with lyophilized camu camu alongside physical activity found decreases in abdominal circumference and body weight indices.
A meta-analysis of 13 RCTs (n=749) found that MCTs (principally C8 and C10) versus long-chain triglycerides produced a small but significant reduction in body weight (−0.51 kg) and waist circumference (−1.46 cm). Effects are modest and additive to caloric restriction rather than standalone. A retrospective study found MCT supplementation enhanced weight loss on a VLCKD.
Capsaicin activates TRPV1 receptors to stimulate thermogenesis, increase energy expenditure by ~50 kcal/day, and reduce appetite. A systematic review and meta-analysis (British Journal of Nutrition) found capsaicin intake significantly reduced ad libitum energy intake, and a 12-week double-blind RCT found decreased percent body fat vs. placebo.
Capsaicinoids are the class of compounds in chili peppers (including capsaicin and dihydrocapsaicin) that activate TRPV1 receptors to increase thermogenesis, fat oxidation, and satiety while reducing energy intake. Multiple systematic reviews and meta-analyses confirm their efficacy for reducing energy intake and body fat percentage, with an estimated ~50 kcal/day increase in energy expenditure.
Capsanthin inhibits adipogenesis and promotes lipolysis in cell models, and reduces body weight in multiple high-fat-diet rodent studies. Its anti-obesity activity involves adrenoceptor-β2 agonism, AMPK activation, and suppression of adipogenic transcription factors.
Capsaicin reduces ad libitum energy intake, stimulates thermogenesis through sympathetic nervous system activation and brown adipose tissue engagement, and modestly reduces body fat in RCTs. A meta-analysis found capsaicinoid ingestion before meals reduced energy intake by approximately 74 kcal per meal.
Caralluma fimbriata is an edible succulent used in India as an appetite suppressant during famine and long hunts. A 2021 PMC systematic review and meta-analysis of 7 clinical trials found C. fimbriata significantly reduced waist circumference and showed trends toward appetite suppression and weight reduction.
Two human clinical trials have evaluated caraway extract for weight and body composition in overweight/obese women, both showing significant reductions in weight, BMI, and body fat percentage versus placebo. Caraway was a traditional ingredient in anti-obesity preparations, and these findings partially validate that traditional use.
Clinical and animal evidence suggests cardamom may support weight-related metabolic parameters. A 2021 narrative review noted cardamom's activity on obesity-related MetS parameters. Animal studies show cardamom powder prevents obesity in high-fat diet models. Human clinical trials primarily show improvements in related metabolic factors (triglycerides, insulin resistance, liver enzymes) in overweight/obese populations, but direct evidence on body weight reduction in humans is limited.
Casein supplementation has been studied for body composition improvement, including fat loss and lean mass preservation during caloric restriction. Its high satiety value and sustained protein release support caloric control and muscle retention. Clinical research supports casein's use in weight management formulations, particularly when combined with exercise.
Green tea catechins in combination with caffeine produce modest but statistically significant reductions in body weight, BMI, and waist circumference. A meta-analysis of 15 RCTs found catechins combined with caffeine—at doses under 500 mg/day over 12 weeks—significantly reduced body weight and BMI. Catechins alone, without caffeine, show inconsistent weight effects.
Cowpea consumption is associated with reduced risk of obesity in epidemiological data, attributed to its low glycemic index, high protein and fiber content promoting satiety, and inhibition of carbohydrate-digesting enzymes. A 2025 human trial found that cowpea induced lower hunger sensation and higher satiety compared to glucose control.
Cauliflower is very low in calories and high in fiber, contributing to satiety and energy density reduction. Sulforaphane has shown anti-obesity effects in preclinical models by inhibiting adipocyte differentiation and lipid accumulation. Epidemiological data associates cruciferous vegetable intake with weight management.
Multiple RCTs and a meta-analysis in the British Journal of Nutrition confirm capsaicin supports modest weight loss in overweight and obese subjects through thermogenesis, increased fat oxidation, and appetite suppression. Effect sizes are small and meaningful only within a controlled-diet context.
Preclinical studies in rodents show that A. aspera seed extract inhibits pancreatic lipase and amylase, suppresses body weight gain on a high-fat diet, and reduces adipose tissue and serum lipid parameters. A PubMed-indexed PMC study provides the primary evidence.
Chen Pi's PMFs and volatile oils have demonstrated anti-obesity effects in animal models and a small clinical trial through AMPK activation, inhibition of adipogenesis, and reduction of adipose tissue weight. A Citrus peel pellet human clinical study showed significant BMI reduction.
A meta-analysis of 8 RCTs (372 participants) found chia supplementation led to a meaningful reduction in waist circumference. Effects on BMI are not statistically significant in pooled analyses. A University of Toronto RCT in obese diabetics showed 4 lbs of weight loss over 6 months with 30 g/day chia vs ~0.5 lbs in controls.
Chickpea protein supplementation in ad libitum diets is associated with reduced spontaneous energy intake and modest improvements in body weight management. The satiating effect of chickpea protein slows gastric emptying and raises anorexigenic hormone levels. A chickpea protein hydrolysate attenuated weight gain and modulated inflammation markers in a high-fat-diet mouse model.
Animal studies have demonstrated that S. media extracts reduce body weight, adipose tissue, and fat deposition in rodent obesity models via lipase inhibition and anorexic effects. Traditional use as an anti-obesity remedy is also documented. No human clinical trials have been conducted.
A 2024 systematic review and meta-analysis of 32 RCTs found chicory inulin-type fructan supplementation significantly reduced body weight, BMI, fat mass, and waist circumference compared to placebo, with effects consistent across different health status groups.
Chlorogenic acid, the principal bioactive in green coffee bean extract, inhibits glucose-6-phosphatase to reduce hepatic glucose output and inhibit intestinal glucose absorption, supporting weight and fat management. A 2020 meta-analysis of RCTs found green coffee bean extract containing chlorogenic acid significantly reduced body weight, BMI, and waist circumference versus placebo.
Thylakoid supplementation has been evaluated for weight management in multiple human RCTs, all reviewed in a 2020 systematic review of 8 trials. By slowing fat digestion and promoting satiety hormone release (CCK, leptin, GLP-1) while suppressing ghrelin, thylakoids support calorie reduction. Studies show modest but consistent reductions in body weight, BMI, and cravings in overweight individuals when thylakoids are combined with meals.
A 2026 systematic review and meta-analysis of 7 RCTs found no significant overall effect of chokeberry on body weight. Individual trials in metabolic syndrome patients report minor weight-associated improvements correlated with polyphenol intake. Animal studies show chokeberry prevents obesity; human evidence is currently inconclusive.
Multiple meta-analyses and a Cochrane review have examined chromium supplementation for weight management in overweight and obese adults. Results consistently show a small but statistically significant reduction in body weight and body fat percentage, though the magnitude is considered clinically negligible. The Cochrane Review characterized the effect as of 'debatable clinical relevance' with low overall evidence quality.
Chromium, particularly as chromium picolinate, potentiates insulin signaling and is used to reduce carbohydrate cravings and body fat. The NIH ODS notes that some clinical trials show small reductions in body weight and fat mass, though evidence is mixed. A systematic review found chromium picolinate produced a modest but statistically significant weight loss versus placebo.
Cinnamon (Cinnamomum verum/cassia) contains cinnamaldehyde and other polyphenols that improve insulin sensitivity, slow gastric emptying, and reduce postprandial glucose, indirectly supporting weight management. Multiple RCTs and meta-analyses in overweight adults with metabolic dysfunction show significant reductions in body weight and waist circumference with 1–3 g/day supplementation.
Several randomized, double-blind, placebo-controlled trials have demonstrated that CQR-300 (300 mg/day) produces significant reductions in body weight, body fat percentage, and waist circumference in overweight and obese participants over 8–10 weeks. A Nature Scientific Reports RCT also showed decreased waist circumference and proposed a mechanism of white adipocyte browning via UCP1 upregulation.
A randomized, double-blind, placebo-controlled trial found that 400 mg/day of Moro blood orange (C. sinensis) extract for 12 weeks significantly reduced body weight, BMI, waist, and hip circumference in overweight adults. Anthocyanins from Moro orange inhibit fat accumulation via antioxidant, anti-inflammatory, and metabolic pathway modulation.
CLA, a fatty acid found naturally in dairy and beef, inhibits lipogenesis and promotes fat oxidation and lipolysis in adipose tissue. A 2011 meta-analysis of 7 long-term RCTs found CLA supplementation produced a small but significant reduction in body weight (mean −0.70 kg) versus placebo over at least 6 months.
RCT meta-analyses find coconut oil does not significantly reduce body weight, BMI, waist circumference, or body fat percentage compared to other fats. MCTs within coconut oil may modestly increase satiety and thermogenesis in short-term studies, but purified MCT oil rather than whole coconut oil drives these effects.
MCTs in coconut milk are metabolized differently from long-chain fats, being rapidly oxidized in the liver and promoting greater energy expenditure (approximately 16% higher thermogenesis vs. LCTs). Animal studies and some human MCT trials show reduced body fat and waist circumference, though high-quality RCTs specific to coconut milk as a whole food are limited.
Coconut oil's MCT content provides theoretical thermogenic and satiety benefits; however, a 2022 meta-analysis of seven RCTs (n=515) found coconut oil did not significantly reduce body weight, waist circumference, or body fat percentage. The thermogenic effect, documented for purified MCT oil, is attenuated in whole coconut oil due to the predominance of lauric acid (C12), which behaves more like a long-chain fatty acid.
Chlorogenic acid-rich coffee extracts have been studied in multiple human RCTs for weight management. A 22-week crossover RCT in 16 overweight adults found green coffee extract reduced body weight by a mean of ~8 lbs with >4% body fat reduction. A separate 12-week double-blind study found 5.4 kg weight reduction with CGA-standardized extract versus placebo.
Coix seed extracts have demonstrated anti-obesity effects in multiple rodent models via suppression of lipogenesis, fat accumulation, and appetite-related pathways. A human yogurt trial also showed modest weight-related metabolic improvements.
Coleus forskohlii root extract contains forskolin, which activates adenylate cyclase to increase cAMP levels, promoting lipolysis and fat mobilization. A 12-week double-blind RCT in 15 obese men found 500 mg/day of 10% forskolin extract significantly decreased body fat and increased lean body mass versus placebo.
Collard greens provide approximately 34 calories per cooked cup while delivering 7–8g of fiber, making them a high-satiety, low-energy-density food. Their low glycemic index (approximately 15) promotes stable blood glucose, reducing hunger-driving insulin surges. WebMD notes that low-GI foods help people feel fuller longer, supporting weight management.
Berberine from Coptis chinensis demonstrates anti-obesity effects in animal models and preliminary human studies, reducing adiposity, improving insulin sensitivity, and modulating adipokines and gut microbiota. Clinical meta-analyses confirm BMI and waist circumference reductions in metabolic syndrome patients.
Corosolic acid is the primary bioactive triterpenoid in banaba leaf that acts as an insulin mimetic, promoting GLUT4-mediated glucose uptake and inhibiting alpha-glucosidase, reducing postprandial hyperglycemia and supporting weight management by limiting glucose available for adipogenic conversion.
BCX has been shown to prevent adiposity accumulation in animal models, modulating lipid metabolism via PPAR-α activation and reducing adipocyte hypertrophy. Serum BCX is inversely associated with obesity markers in human observational data, and it reduces metabolic markers in high-fat-diet rodent models.
Cucumber has extremely low caloric density (~16 calories/cup) and very high water content (~96%), making it a documented dietary tool for weight management. An analysis of 13 studies involving 3,628 people found that eating foods with high water and low calorie content was significantly associated with decreased body weight.
Several RCTs in overweight adults show cumin supplementation reduces body weight, BMI, waist circumference, and fat mass. One RCT found cumin produced weight loss equivalent to orlistat. A 2021 systematic review confirmed significant BMI reduction (WMD −0.88 kg/m²) across 8 RCTs.
Small human studies using the YGD combination (including damiana) showed weight loss in overweight adults. In vitro, damiana extract reduced adipocyte differentiation and activated metabolic nuclear receptors. Damiana's individual contribution to weight effects in human studies cannot be isolated from the multi-herb formula.
Clinical evidence for DHA and omega-3 fatty acids in body weight reduction is mixed; most RCTs show no significant effect on body weight alone, but some data support modest reductions in waist circumference. Effects appear most meaningful when omega-3 supplementation is combined with caloric restriction, and triglyceride-lowering effects are well-established even when weight effects are absent.
EGCG is the principal bioactive catechin in green tea responsible for thermogenic and fat-oxidizing effects via COMT inhibition and TRPV1/AMPK pathway activation. Clinical studies at doses of 270–600 mg/day demonstrate modest reductions in body weight, body fat, and waist circumference compared to placebo.
Egg-based breakfasts high in protein improve satiety and may support body composition management. RCT data show that including eggs in the diet of adults with type 2 diabetes reduced waist circumference and percent body fat, and higher-protein egg meals reduce subsequent energy intake compared to lower-protein alternatives.
Eucommia leaf extract has demonstrated anti-obesity effects in multiple rodent models, reducing body weight, visceral and perirenal fat, and improving adipokine profiles. Mechanisms include enhanced thermogenesis, suppressed food intake, increased β-oxidation, and inhibition of lipogenesis. No human weight-loss RCTs have been published.
Fava beans' combination of protein (~13 g/cup cooked), dietary fiber, and relatively low caloric density supports satiety, reduces subsequent energy intake, and may facilitate weight management. Clinical trials of legume-rich diets show weight maintenance or modest weight loss advantages compared to control diets.
Fenugreek seeds contain galactomannan fiber and saponins that slow gastric emptying, promote satiety, reduce appetite, and improve insulin sensitivity. Multiple RCTs show fenugreek supplementation significantly reduces appetite, caloric intake, and body fat in overweight individuals, with effects partly mediated through glucose and insulin regulation.
A meta-analysis of 45 RCTs found whole flaxseed supplementation significantly reduced body weight, BMI, and waist circumference. Effect sizes are modest and most pronounced with whole/ground flaxseed versus oil, and in individuals with obesity or metabolic syndrome.
Forskohlii root is the botanical source of forskolin and shares the same evidence base as Coleus forskohlii extract. Clinical trials show significant decreases in body fat and increases in lean body mass in obese men at 500 mg/day (10% extract) over 12 weeks. Traditional Ayurvedic medicine used the root for obesity and metabolic disorders.
Human trials with inulin-type fructans (which include FOS) show significant reductions in body weight and body fat mass in overweight/obese adults consuming higher doses (e.g., 21 g/day oligofructose for 12 weeks). FOS-specific weight effects in humans are more modest, likely via GLP-1/PYY-mediated appetite suppression and improved insulin sensitivity.
Fucoxanthin is a carotenoid from brown seaweed that promotes weight loss by increasing resting energy expenditure and fatty acid oxidation, and by suppressing adipocyte differentiation. The NIH ODS references one 16-week clinical trial (Xanthigen) showing mean body weight loss of 6.3–6.9 kg versus 1.4 kg in placebo.
Gamma oryzanol has shown protective effects against diet-induced weight gain and obesity-associated metabolic dysfunction in animal models. Preclinical studies demonstrate reductions in body weight, visceral fat, and metabolic dysfunction markers. A 2025 review notes it ameliorates obesity-related metabolic disorders through improved skeletal muscle energy metabolism.
Epidemiologic and interventional evidence links chickpea and pulse consumption to modest reductions in body weight and waist circumference. A meta-analysis in the American Journal of Clinical Nutrition (21 trials) found daily pulse consumption associated with weight loss even without intentional caloric restriction. Observational studies report that chickpea consumers have lower body weight, smaller waist circumference, and reduced obesity prevalence.
Garcinia cambogia rind extract contains hydroxycitric acid (HCA), which inhibits ATP citrate lyase, reducing de novo fatty acid synthesis, and may suppress appetite. The NIH ODS and StatPearls acknowledge clinical trial evidence, though meta-analyses report modest and inconsistent weight loss, typically 2 kg over 2–12 weeks versus placebo.
Geniposide from Gardenia jasminoides has been shown to inhibit body weight gain and improve lipid and glucose markers in obese animal models. A human study of middle-aged obese women incorporating gardenia fruit observed changes in body composition and metabolic hormones. Genipin promotes fat oxidation via PPAR-α and reverses obesity-induced beta-cell dysfunction.
Ginger (Zingiber officinale) contains gingerols and shogaols that activate TRPV1 receptors to increase thermogenesis, enhance satiety via serotonin receptor modulation, and improve lipid metabolism. A 2019 meta-analysis of RCTs found ginger supplementation significantly reduced body weight, waist-to-hip ratio, and fasting glucose in overweight/obese adults.
Glucomannan, a highly viscous soluble fiber from konjac root, absorbs water in the stomach to form a gel, slowing gastric emptying and promoting satiety. An 8-week double-blind RCT in 20 obese subjects found a mean weight loss of 5.5 lbs with 3 g/day versus placebo. A 2025 systematic review of RCTs found KGM supplementation (≥5 g/day, ≥12 weeks) associated with mean reductions of 3.18 kg body weight and 1.49 kg/m² BMI.
A clinical study in metabolic syndrome patients found that 14 g/day dried goji berry for 45 days significantly reduced waist circumference. Reviews characterize LBP as having anti-obesity properties. Goji berry is low in calories and high in fiber, and its prebiotic effects on the gut microbiome may support weight regulation. Dedicated weight-loss RCTs in humans are limited.
A clinical trial in obese adults demonstrated that 500 mg of amla extract twice daily for 90 days significantly reduced visceral and subcutaneous fat, BMI, and waist circumference while increasing skeletal muscle mass.
Grains of paradise (Aframomum melegueta), a West African spice, contains 6-paradol which activates TRPV1 receptors to induce thermogenesis and 'beige' white adipose tissue, increasing energy expenditure and reducing visceral fat. A human RCT found a standardized extract significantly increased whole-body energy consumption and reduced visceral fat in healthy men.
Several RCTs have evaluated grapefruit for weight management, with modest but inconsistent results. A meta-analysis of 3 RCTs in overweight/obese adults found no significant reduction in body weight but a significant decrease in systolic blood pressure. Individual trials have noted significant reductions in waist circumference with regular grapefruit consumption.
Green tea and its catechin-rich extracts—particularly EGCG—increase thermogenesis and fat oxidation, partly by inhibiting the enzyme COMT and extending norepinephrine activity. Multiple RCTs and meta-analyses demonstrate modest but significant reductions in body weight and waist circumference, especially when combined with caffeine.
Guarana (Paullinia cupana) seeds contain high concentrations of caffeine (3–5% by weight, higher than coffee) along with theobromine and theophylline, providing robust thermogenic, lipolytic, and appetite-suppressing effects. A clinical study in healthy adults found guarana-containing supplements increased energy expenditure and reduced body weight as part of combination weight management regimens.
Gymnemic acids are the active saponin constituents of Gymnema sylvestre that block intestinal glucose absorption (via SGLT-1 inhibition) and suppress sweet taste receptor activity, reducing carbohydrate caloric intake. Clinical studies in overweight and diabetic subjects show reductions in body weight and blood glucose associated with standardized extracts.
Clinical trial evidence shows Hibiscus sabdariffa extract (HSE) reduced body weight, BMI, body fat, and waist-to-hip ratio in obese adults over 12 weeks. Preclinical data demonstrate HSE inhibits hepatic lipogenesis and preadipocyte adipogenesis. The 2025 umbrella review confirms anti-obesity effects as one of HS's cardiometabolic benefits.
In high-fat-diet (HFD) male mice, 7-HMR at 3 mg/kg body weight for 60 days limited body weight gain by 11% and fat mass gain by 11% compared to untreated HFD controls. Adipocytes were smaller and liver steatosis was reduced by 62%. ENL and enterodiol (HMR's gut metabolites) also inhibited adipogenesis in vitro by 40%.
HMRlignan reduced body weight gain by 11% and fat mass by 11% in high-fat diet mice, with hepatic steatosis reduced by 62%. HMR metabolites enterolactone and enterodiol inhibited adipocyte differentiation by ~40% in culture via PPARγ pathway suppression. All evidence is preclinical; no human weight management RCT has been conducted.
Xanthohumol from hops attenuated weight gain in multiple obese rodent models by suppressing SREBP activation, reducing fat absorption, and modulating adipokines. A hop bitter extract (Amarasate®) reduced acute energy intake and modulated appetite hormones in a human crossover RCT. Human evidence is early-stage.
Vaccinium anthocyanins have been studied in obesity models and human RCTs for anti-obesity effects. A meta-analysis of 11 RCTs found anthocyanin supplementation produced a small but significant reduction in BMI. Huckleberry shares the relevant anthocyanin classes. Mechanistic evidence includes inhibition of lipogenesis, AMPK activation, and reduced adipogenic gene expression.
Preclinical and cell-based studies show that Dolichos lablab seed extract and its saponin constituent chikusetsusaponin IVa inhibit adipocyte differentiation and reduce high-fat diet-induced weight gain in rodent models. A metabolomics study found anti-obesity effects comparable to milk thistle at lower doses. No human trials exist.
Hydroxycitric acid (HCA) from Garcinia cambogia inhibits ATP citrate lyase, blocking de novo fatty acid synthesis, and may increase serotonin to suppress appetite. A 2011 meta-analysis of 12 RCTs found HCA-containing supplements produced statistically significant weight loss of ~0.88 kg vs. placebo, though one large 12-week RCT showed no significant benefit.
In a high-fat-diet (HFD) mouse model, HMR at 3 mg/kg body weight limited body weight gain by ~11% and fat mass accumulation by ~11% compared to HFD controls. HMR also inhibited adipocyte differentiation in the 3T3-L1 cell model. No human weight management trials have been published.
Randomized controlled trials show gum arabic supplementation reduces BMI, body fat percentage, and visceral adiposity index. A double-blind placebo-controlled RCT in healthy adult females found significant reductions in BMI and body fat. A further RCT in type 2 diabetic patients showed significant decreases in BMI and visceral adiposity.
A 2022 meta-analysis of 15 RCTs found inositol supplementation produced a statistically significant but modest reduction in BMI (WMD −0.41 kg/m²), with the greatest effects in overweight/obese individuals and those with PCOS. Myo-inositol appears more effective than other forms. The absolute magnitude of weight reduction is small, suggesting inositol serves best as an adjunct to other interventions.
Inulin is a soluble prebiotic fiber from chicory, Jerusalem artichoke, and other plants that promotes satiety via GLP-1 and PYY stimulation, reduces energy intake, and modulates gut microbiota composition. Multiple RCTs demonstrate inulin supplementation significantly reduces body weight, fat mass, and caloric intake in overweight adults.
Thyroid hormones, dependent on iodine, set the basal metabolic rate; iodine deficiency causing hypothyroidism slows metabolism and promotes weight gain. Cleveland Clinic and NIH-affiliated sources confirm weight gain as a direct symptom of iodine-deficiency hypothyroidism. Correcting deficiency can reverse this metabolic slowing. No evidence exists for weight loss benefit from iodine supplementation in iodine-sufficient individuals.
Irvingia gabonensis (African wild mango) seed extract inhibits adipogenesis via PPAR-γ suppression, inhibits α-amylase and α-glucosidase, and modulates leptin and adiponectin levels. A systematic review of RCTs found administration of 200–3150 mg/day for 4–10 weeks produced statistically and clinically significant weight loss and reduced waist circumference.
Animal models consistently show IMO prevents HFD-induced adiposity and weight gain, modulating hypothalamic appetite-regulating genes. A small human single-arm trial found IMO combined with high-protein diet reduced BMI, body fat percentage, and waist circumference. Evidence remains preliminary in humans.
A 12-week randomized, double-blind, placebo-controlled trial (n=80) of actiponin—a heat-processed G. pentaphyllum extract—found significant reductions in total abdominal fat area, body weight, body fat mass, percent body fat, and BMI vs. placebo in obese Korean adults.
Kale is low in calories and carbohydrates but high in fiber and water, providing satiety while contributing minimally to energy intake. An 8-week kale powder study in metabolic syndrome subjects found maintained abdominal circumference. Mouse studies show kale attenuates HFD-induced fat accumulation. Kale's low glycemic index and fiber content support weight management.
Human clinical evidence links kelp components—particularly alginate and fucoxanthin—to modest weight and body fat reduction. A clinical trial of Xanthigen (fucoxanthin + pomegranate oil) in 151 non-diabetic obese women showed reductions in body weight, waist circumference, and liver fat. An 8-week RCT with iodine-reduced kelp powder found significant decreases in body fat percentage in overweight men. Evidence is promising but limited.
White kidney bean extract (WKBE) and whole kidney beans have been studied in multiple clinical trials and shown to promote significant weight loss, reductions in waist circumference, and body fat compared to placebo. Mechanisms include inhibition of starch digestion, reduced caloric absorption, and enhanced satiety.
A systematic review and meta-analysis of RCTs found that L-arginine supplementation most significantly reduced waist circumference (P=0.001) compared to placebo. A pilot study in centrally obese subjects reported significant reductions in body weight, BMI, and waist-to-hip ratio over 12 weeks. Human trial results for overall weight loss remain inconsistent and modest.
L-carnitine is essential for mitochondrial long-chain fatty acid transport and oxidation, and supplementation has been studied for weight and fat loss. A 2020 systematic review and meta-analysis of 37 RCTs (n=2292) found l-carnitine supplementation significantly decreased body weight (−1.21 kg), BMI (−0.24 kg/m²), and fat mass (−2.08 kg) versus placebo.
In a 12-week RCT in obese women with metabolic syndrome, 4 g/day L-histidine reduced waist circumference and fat mass. Observational data in 88 obese subjects also linked higher dietary histidine to lower BMI. The appetite-suppressing and lipolytic effects of hypothalamic histamine derived from histidine provide a plausible mechanism.
Leucine exerts overlapping effects on satiety, preservation of lean mass during caloric restriction, and improvement of lipid metabolic markers that are relevant to weight management. Animal studies show leucine-supplemented diets attenuate fat mass expansion without loss of lean body mass. Human evidence is primarily indirect, arising from high-protein diet trials in which leucine is the key signaling amino acid.
Lactobacillus gasseri is the most extensively studied probiotic strain for weight and fat reduction in humans. Multiple RCTs including a 12-week double-blind trial in 87 obese adults found L. gasseri SBT2055 significantly reduced abdominal visceral fat, BMI, waist and hip circumference, and body weight versus placebo.
L. paracasei BEPC22 (in a dual-strain product with L. plantarum BELP53) significantly reduced body fat percentage, body fat mass, body weight, and BMI in overweight adults in a 12-week RCT. L. paracasei K56 at 10⁹ CFU/day for 60 days reduced body fat mass, body fat percentage, visceral fat area, and waist circumference in obese individuals.
RCTs show that specific L. plantarum strains (K50, PL-02) reduce total cholesterol, triglycerides, and body fat percentage, and alter gut microbiota composition in overweight individuals. Muscle mass increase from PL-02 indirectly supports weight composition improvements.
Lactobacillus rhamnosus CGMCC1.3724 has demonstrated sex-specific weight loss effects in clinical trials. A 2014 double-blind RCT in 125 obese men and women over 24 weeks found women taking L. rhamnosus lost significantly more weight (1.8 kg more) and continued to lose weight during the maintenance phase, unlike placebo, via modulation of appetite-regulating hormones and gut microbiota.
Lemon polyphenols have shown anti-obesity effects in preclinical models. A human clinical study (Kim et al., 2015) of a lemon detox diet in 84 overweight women found significant reductions in body weight, body fat, and inflammatory markers. Evidence for lemon water alone as a weight management tool is limited.
A prospective investigation using Nurses' Health Study data examined associations between urinary enterolactone/enterodiol excretion (lignan metabolite biomarkers) and 10-year weight change in US women. Preclinical studies consistently suggest lignans regulate body weight. A 2025 PMC review identifies multiple anti-obesity mechanisms including modulation of appetite hormones, lipid metabolism, and visceral fat accumulation.
Animal studies demonstrate D-limonene reduces body weight, food intake, fat cell size, and hepatic lipid accumulation in obese and high-fat-diet models. It has been described as a mild appetite suppressant. No controlled human clinical trials on weight management have been published.
Red-skin extracts of lotus seeds reduce obesity characteristics in high-fat diet mice by regulating lipoprotein lipase activity. Lotus seed components suppress adipogenesis and lipid accumulation. Clinical data come primarily from lotus leaf studies; lotus seed-specific human weight trials are absent.
Oligonol, a lychee-derived polyphenol extract, has shown evidence for reducing visceral (abdominal) fat and supporting weight maintenance in human clinical studies. A small 12-week RCT in overweight/obese women found oligonol recipients maintained weight while the placebo group gained weight, and also had lower triglycerides. Oligonol reduces visceral fat formation through cortisol-lowering and hormonal regulation in adipose tissue.
Despite being calorie-dense, macadamia nut consumption is not associated with weight gain and may support healthy weight maintenance. The 2023 MAC Study (n=35, 8-week RCT) showed no gains in weight, BMI, or body fat despite macadamias comprising 15% of daily energy intake. A broader body of nut research links regular consumption to lower long-term weight gain risk.
Human RCT evidence shows magnolia/phellodendron extract prevents stress-induced weight gain in overweight women by reducing cortisol and emotional eating. Animal studies show magnolia extract reduces body fat mass and lowers triglycerides, cholesterol, and insulin resistance. The human evidence for weight loss (as opposed to weight maintenance) is weak and limited to combination products.
Animal studies show maitake extract reduces body weight, visceral fat, and hepatic lipid accumulation in high-fat diet mouse models, partly via microbiome modulation and improved insulin sensitivity. A maitake alpha-glucan study in KK-Ay diabetic mice significantly decreased body weight alongside metabolic markers. Human weight-specific controlled trials are absent.
A 24-week RCT in adults with prediabetes found daily mango consumption (300 g) significantly reduced body fat percentage (trend, p=0.05) and increased fat-free mass compared to a calorie-matched control. An 8-week RCT in T2D subjects showed reductions in body weight and waist circumference versus a bread control group.
Clinical trials using a mangosteen/Sphaeranthus indicus combination (Meratrim) in obese subjects demonstrated significant weight loss (5.1 kg vs 1.3 kg in controls) over 16 weeks. An 8-week study in 40 subjects found mangosteen juice blend reduced BMI. α-Mangostin inhibits pancreatic lipase and fatty acid synthase, reducing fat assimilation.
In a rat model of diet-induced metabolic syndrome, maqui berry supplementation reduced weight gain over 14 days alongside improvements in glucose, cholesterol, and blood pressure. Human evidence is indirect: reduced postprandial insulin spikes and improved glucose metabolism may support weight management by limiting fat storage signals. No dedicated human weight-loss RCT for maqui exists.
Medium-chain triglycerides (C8–C12 fatty acids) are rapidly absorbed and oxidized in the liver, increasing thermogenesis, satiety, and ketone production compared to long-chain triglycerides. Multiple RCTs and meta-analyses show MCT oil consumption reduces body weight, waist circumference, and fat mass versus LCT comparators.
A meta-analysis of 19 studies found millet consumption reduced BMI by 7% in overweight and obese individuals, moving values from above-normal toward healthy ranges. Millet's high fiber content, low glycemic index, and complex carbohydrate composition promote satiety and reduce overall caloric intake.
Multiple preclinical studies and some human RCT data have examined M. charantia for anti-obesity effects including reduction of body weight, BMI, and fat mass. A systematic review of RCTs found no statistically significant effect on body weight or BMI versus placebo in human trials, though animal model evidence is substantial. The data remain inconsistent.
As a zero-calorie, zero-carbohydrate sweetener, monk fruit extract enables caloric reduction when substituted for sugar in the diet, which is the primary mechanism supporting weight management. No direct human clinical trials have measured body weight as a primary endpoint specifically for monk fruit. Animal studies show that mogroside V and VI fractions prevented increases in body and abdominal fat weight. Evidence from other low-calorie sweeteners supports the general principle of calorie reduction aiding weight management.
Clinical evidence suggests Morus leaf extract can enhance weight loss as an adjunct to caloric restriction. One RCT in 46 overweight individuals on a low-calorie diet reported approximately 3-fold greater weight loss with mulberry extract versus placebo. Animal studies confirm anti-obesity effects via multiple mechanisms.
Clinical studies confirm mulberry leaf extract reduces postprandial glucose and insulin spikes that drive fat storage. Preclinical evidence in obese mice demonstrates reduced weight gain and fat accumulation. A Frontiers 2024 review summarised clinical and preclinical support for Morus alba in weight management.
Naringin and naringenin reduce body weight in obese animal models without decreasing food intake, via increased energy expenditure. A human case study observed a 2.3 kg weight reduction over 8 weeks with naringenin. Clinical studies in dyslipidemic patients found reduced BMI with naringin. Blood naringenin levels are inversely correlated with obesity in population studies.
Human clinical trials show nopal produces modest effects on body weight and BMI, generally within multi-ingredient protocols or calorie-restricted diets. A 2-month RCT demonstrated significant reductions in body weight, BMI, and waist circumference in metabolic syndrome subjects using a nopal-containing formula. Solo nopal supplementation has shown at most slight reductions in waist circumference without significant changes in body weight or BMI. Evidence for nopal alone as a weight-loss intervention remains weak.
Two human randomized, double-blind, placebo-controlled trials support C. rotundus rhizome extract (standardized to stilbenes: scirpusin A, scirpusin B, piceatannol) for weight reduction in obese individuals. Significant reductions in body weight, BMI, waist circumference, and lipid levels were recorded. Animal data show inhibition of adipogenesis, lipase, and amylase.
Oat β-glucan promotes satiety via viscosity and slowed gastric emptying, and clinical trials support its role in weight management, particularly in overweight and diabetic populations. A 30-day RCT with 1-year follow-up in overweight T2DM found whole oat intake improved weight management alongside glycolipid metabolism.
RCT meta-analyses have investigated okra's effects on body weight and BMI, finding no significant overall reduction. A 2025 meta-analysis of six RCTs found non-significant effects on body weight (WMD: −0.83 kg) and BMI. Evidence from one RCT noted reduced dietary intake and appetite in diabetic nephropathy patients receiving okra extract.
OA reduces fat accumulation and attenuates obesity in high-fat-diet animal models, partly by modulating lipid metabolism via PPARγ and inhibiting adipogenesis. In HFD-fed mice, OA treatment suppressed increases in fat mass and body weight.
Diets enriched in oleic acid (MUFA) have been associated with favourable body composition outcomes compared to diets high in saturated or polyunsaturated fats in several human intervention studies. A systematic review of human trials found that high-oleic acid diets led to reduced adiposity, particularly android fat mass, versus PUFA-rich diets. OEA, synthesised from oleic acid, also plays a role in appetite suppression and fat oxidation.
Clinical evidence suggests EVOO-rich Mediterranean diets modestly support healthy weight and body composition compared to low-fat diets, particularly reducing visceral fat. A 2018 double-blind RCT found EVOO improved body composition and blood pressure in women with excess body fat. Meta-analytic data show EVOO-enriched diets reduce waist circumference and BMI.
Epidemiological and limited clinical evidence link higher omega-3 status with lower measures of adiposity. Studies in animal models suggest LC n-3 PUFAs contribute to weight management, and some human trials indicate modest effects on body composition. Overall, evidence is exploratory; omega-3 is not established as a weight-loss treatment.
Diets high in oleic acid (omega-9), particularly within Mediterranean patterns, are associated with better weight management and metabolic resilience compared to high-saturated-fat or high-refined-carbohydrate diets. OA promotes anti-obesity mechanisms including adiponectin upregulation and modulation of adipocyte differentiation signals.
A meta-analysis of 14 RCTs found that onion supplementation significantly improved body fat percentage, a key indicator of healthy body composition. Onion's quercetin may inhibit adipogenesis and increase energy expenditure. Human trials show modest but statistically significant improvements in body composition metrics.
Blood orange (Moro cultivar) standardised extract has been evaluated in an RCT for weight loss in overweight adults, with anthocyanins like cyanidin 3-glucoside implicated in modulating adipogenic pathways. Pre-clinical and clinical data support modest reductions in body weight and fat accumulation. Effect is attributed to antioxidant, anti-inflammatory, and metabolic mechanisms.
POA is a lipokine that paradoxically reduces lipogenesis in toxic storage sites (liver, muscle) while promoting safe storage in adipose tissue. Observational data from large cohorts associate higher circulating POA with lower BMI and waist circumference in some populations, though endogenous POA can also track with obesity as a de novo lipogenesis byproduct.
Pea protein's satiety-promoting effects—via CCK, GLP-1, and PYY stimulation—reduce subsequent caloric intake, supporting energy balance. High-protein pea supplement use has been studied in the context of body composition alongside resistance training, showing maintenance of lean mass.
Multiple RCTs and observational data show that regular peanut consumption does not promote weight gain and can support weight management. An RCT incorporating 70 g/day peanuts in an energy-restricted diet achieved ~7.5% body weight loss comparable to a low-fat diet. Epidemiological data confirm nut consumers tend to weigh less than non-consumers.
Pears are low in calories (~57 kcal/100 g) and high in water and fiber, both of which promote satiety and reduce overall energy intake. Epidemiological studies link dietary fiber intake to lower body weight. Pear pomace soluble dietary fiber reduced obesity-index and body weight in high-fat-diet animal models via gut microbiota modulation.
Pectin supplementation has been associated with reduced body weight and fat mass in animal obesity models and in human trials using pectin-enriched formulations. Its mechanisms include enhanced satiety, reduced caloric intake, improved microbiota composition, and increased butyrate production that opposes adipogenesis.
Phaseolamin is an alpha-amylase inhibitor derived from white kidney beans (Phaseolus vulgaris) that blocks starch digestion, reducing carbohydrate caloric absorption. A 35-day RCT in obese subjects showed 2.24 kg weight loss with Phaseolus vulgaris extract versus 0.29 kg with placebo. A 2024 double-blind RCT confirmed weight and fat loss with standardized extract over 12 weeks.
Berberine from P. amurense activates AMPK, reduces fat accumulation in adipocytes, and lowers leptin and glycerol secretion. A 2025 meta-analysis of RCTs found berberine significantly reduced BMI (WMD −0.435 kg/m²) and waist circumference (WMD −3.270 cm). The Relora blend (P. amurense + Magnolia) reduced stress-related eating and weight gain in a clinical pilot with overweight premenopausal women.
A meta-analysis of 79 RCTs found phytosterol supplementation did not significantly reduce body weight, fat mass, or waist circumference, but produced a small statistically significant BMI decrease (−0.063 kg/m²). Phytosterols appear to have negligible direct effects on body weight in humans.
Psyllium (Plantago ovata) promotes satiety, reduces hunger, and supports weight management. Clinical trials confirm it reduces energy intake and body weight. It is recognized by the FDA and the 2024 PMC review as providing weight/energy-intake reduction benefits among its five major health claims.
Platycodon root extract has demonstrated anti-obesity effects in multiple preclinical models and one human RCT. Platycodin D inhibits lipase and intracellular triglyceride accumulation, while PG polysaccharides reduce body weight and adiposity in high-fat-diet mice. A double-blind RCT in 108 Korean overweight adults showed significant reduction in body fat mass and abdominal fat.
A 12-week randomized, double-blind, placebo-controlled trial in 108 overweight Korean adults found that 571 mg/day platycodon root extract significantly reduced body fat mass, body fat percentage, and abdominal/subcutaneous fat areas compared to placebo. Animal studies consistently show anti-adipogenic effects via PPARγ and C/EBPα downregulation.
A 2025 cardiometabolic meta-analysis of RCTs found pomegranate supplementation significantly reduced body weight (SMD: −0.14 kg) and BMI (SMD: −0.17 kg/m²) vs. placebo. A dedicated RCT also showed reductions in body fat and waist circumference with pomegranate peel extract in NAFLD patients. Effects are modest.
Pomelo's high fiber and water content promote satiety, while naringin and naringenin from its peel inhibit adipogenesis and activate lipid-metabolizing enzymes. Animal studies show pomelo peel extract reduces body weight and improves lipid profiles in high-fat diet models by activating PPARα and GLUT4 pathways. Human observational data associate naringenin blood levels inversely with waist circumference and obesity.
RCT evidence shows an Opuntia-derived fiber complex (Litramine) significantly reduced body weight, BMI, body fat, and waist circumference in overweight adults over 12 weeks. However, a broader meta-analysis found OFI does not consistently reduce body weight across all trials, though reductions in percentage body fat were confirmed.
Targeted colonic delivery of propionate via inulin-propionate ester significantly prevented weight gain and reduced intra-abdominal adipose tissue in a 24-week human RCT in overweight adults. The mechanisms include GLP-1/PYY-mediated reduction in energy intake, inhibition of hepatic lipogenesis, and improved adipose tissue lipid buffering. Chronic dietary propionate from food preservatives, at higher doses, has conversely been linked to gradual weight gain in animal models.
An ancillary analysis of the 12-month Prune Study RCT found that 100 g/day prunes produced a significant reduction in android (abdominal) total mass versus controls, though BMI, lean mass, and overall fat distribution were unaffected. A meta-analysis of 169 trials found dried fruits consumed at ≤50 g/day were associated with decreased adiposity. Evidence is mixed and modest.
Psyllium (Plantago ovata) husk is a soluble viscous fiber used to promote satiety and reduce caloric intake by forming a thick gel in the gastrointestinal tract. Multiple RCTs show psyllium supplementation before meals significantly increases satiety, reduces hunger, and produces modest reductions in body weight in overweight individuals.
P. marsupium is documented in Ayurvedic medicine for 'medodosa' (obesity), and preclinical studies show it reduces body weight and fat accumulation in diabetic and high-fat diet animal models. Human clinical evidence remains limited.
Pumpkin flesh is very low in calories (~50 kcal/cup) yet high in fibre, water content, and micronutrients, making it a satiating, nutrient-dense food that supports energy-controlled eating patterns. Seeds provide protein and fibre that promote satiety. These nutritional properties are well-documented, though no dedicated weight-loss RCT with pumpkin as the sole intervention exists.
A 2022 preclinical study in high-fat-diet-obese rats demonstrated anti-obesity action by B. diffusa through cannabinoid (CB1) receptor blockade, reducing body weight, adiposity markers, and hepatic lipid accumulation. Traditional use for reducing fluid-related weight gain (via diuresis) and as a mild laxative reducing accumulated toxins is also documented.
A 2023 meta-analysis of RCTs found purslane supplementation significantly reduced body weight (WMD: −1.7 kg, p<0.003) and BMI (WMD: −0.6, p<0.04), with doses below 1 g/day appearing most effective for adiposity reduction. Effects are modest and attributed to anti-inflammatory, lipid-lowering, and metabolic actions rather than direct appetite suppression.
A meta-analysis of 7 RCTs found quinoa did not produce statistically significant reductions in BMI or body weight compared to placebo as a supplement, but dietary substitution trials in pre-diabetic and NAFLD patients showed reduced BMI and waist circumference. Quinoa's high-protein, high-fiber, low-GI profile supports satiety and reduced caloric intake. Evidence supports quinoa as a beneficial grain swap for weight management rather than a standalone weight-loss agent.
Animal studies show radish seed glucosinolate extract prevents weight gain in high-fat diet-induced obesity models and reduces lipid deposition in liver and adipose tissue. Radish leaves have also been linked to gut health and anti-obesity effects in one published rodent study. Human evidence is absent.
Raspberry fruit consumption has been tested in RCTs in overweight/obese individuals for metabolic and body composition outcomes. A 2020 eight-week RCT found no significant change in body weight or anthropometric measures at 280 g/day, though gene expression and metabolomic changes were observed. Raspberry ketone (a distinct aromatic compound) has been evaluated in one multi-ingredient human trial showing modest weight loss. Overall evidence for weight loss per se is weak; metabolic effects (glycemia, insulinemia) are better established.
Clinical evidence supports a role for Relora® in attenuating stress-related weight gain. In Garrison & Chambliss (2006), stress-eating overweight women taking Relora did not gain weight on average over 6 weeks while control subjects gained 1.5 kg. An early pilot suggested Relora maintained healthy cortisol and DHEA levels, supporting body-fat distribution. Effects are primarily indirect, mediated through cortisol reduction.
A meta-analysis of 36 RCTs (PubMed, 2018) found resveratrol significantly reduced body weight, BMI, fat mass, and waist circumference while increasing lean mass versus placebo, with the strongest effects seen in obese subjects. However, a separate meta-analysis found no significant effect on body weight or BMI, highlighting high heterogeneity. Results across trials are inconsistent, and clinical effect sizes are modest.
Green robusta coffee extract (Coffea canephora robusta, standardised for 25% chlorogenic acid) is specifically sourced as the primary material for green coffee bean extract (GCBE) weight-management supplements. Chlorogenic acids inhibit intestinal glucose absorption and curtail hepatic gluconeogenesis, while caffeine increases thermogenesis and lipolysis. A randomised crossover study found that lightly roasted, CGA-rich coffee was slightly superior at inducing changes in body composition in overweight/obese participants.
A 12-week double-blind RCT in 32 preobese subjects (BMI 25–29) found that 100 mg/day rose hip extract significantly decreased abdominal visceral fat (−9.23 cm² versus +3.24 cm² in placebo) and body weight (−1.4 kg). The active constituent tiliroside, a glycosidic flavonoid, is proposed to reduce visceral fat via adiponectin signaling and suppression of PPAR-gamma-mediated lipid accumulation.
Epidemiological studies consistently associate higher whole-grain intake with lower BMI and reduced obesity risk, with rye contributing due to its satiety-promoting fiber and lower energy density compared to refined grain foods. RCTs show rye-based meals reduce desire to eat and improve appetite regulation, mechanistically supporting weight management. Direct long-term weight-loss RCTs with rye as a sole intervention are limited.
Clinical trials show safflower oil (8 g/day, 16 weeks) decreased waist fat and increased lean muscle mass in obese post-menopausal diabetic women. A separate 8-week trial in 75 women found safflower oil supplementation reduced BMI, waist circumference, and body fat. Safflower yellow in obese mice significantly reduced body fat mass via PGC1α-mediated mechanisms.
Clinical evidence suggests saffron may modestly reduce snacking frequency and support appetite control, potentially via serotonergic pathways. However, a 2022 meta-analysis of 25 RCTs found no significant effect on body weight, BMI, or waist circumference overall. A pediatric RCT found significant BMI reductions in obese prediabetic adolescents. Evidence is preliminary and inconsistent.
A randomized, double-blind, placebo-controlled study in 28 obese women found schisandra fruit supplementation trended toward reduced waist circumference and fat mass. A 12-week RCT of schisandra-soybean extract in hyperglycemic subjects showed significant metabolic improvements including reduced LDL and fasting glucose. Preclinical evidence shows anti-obesity effects.
SDG inhibits adipogenesis through the AMPK pathway, reduces visceral fat accumulation, and decreases PPARγ and C/EBPα expression in fat cells. Multiple rodent studies demonstrate significant body weight, adipose tissue mass, and serum lipid reductions. A human RCT showed smaller waist circumference gain with FLC/SDG supplementation in type 2 diabetics.
Sesame's antiobesity effects are documented in preclinical studies and partially in human trials. A 2025 meta-analysis (6 trials, 465 participants in hypertensive populations) documented reductions in BMI (WMD −3.00 kg/m²) with sesame supplementation. Sesame's fiber and protein increase satiety, while sesamin activates PPARα to promote fat oxidation. Evidence is emerging but not as robust as for lipid/glucose effects.
Shiitake supplementation in high-fat-diet rodent models consistently reduced body weight gain, fat mass, and plasma triglycerides. A negative dose-response correlation exists between mushroom supplementation and body weight gain. Beta-glucans promoting fecal fat excretion are a proposed mechanism. Human clinical data are supportive via mushroom-as-meat-replacement trials but isolated shiitake weight studies are limited.
Z. bungeanum extracts and hydroxy-α-sanshool demonstrate anti-obesity effects in high-fat-diet rodent models, reducing adiposity and improving lipid metabolism. Network pharmacology identifies apoptosis of adipocytes as a key mechanistic pathway. No human clinical trial data.
An in vitro study published in IJMS (2023) found that A. julibrissin leaf extract inhibits adipogenesis and promotes browning of white adipocytes via PPARγ-C/EBPs pathway suppression and UCP-1 upregulation, suggesting anti-obesity potential.
Soy protein use in meal replacement programs and RCTs is associated with modest body weight and fat mass reduction. Soy isoflavones reduce visceral adiposity in animal and some human studies. Equol-producer status is inversely associated with obesity risk in observational studies.
Clinical evidence suggests soy isoflavones may modestly reduce waist and hip circumference, particularly in overweight and metabolically compromised individuals. An RCT found waist circumference decreased significantly in soy isoflavone recipients, and soy protein has anti-obesogenic properties attributed partly to isoflavone activity. Soy isoflavones are noted to have anti-obesogenic properties in a PMC review on cardiovascular health.
The most robust clinical evidence for S. indicus concerns weight management. Multiple RCTs and a meta-analysis confirm that its combination with Garcinia mangostana (Meratrim, 800 mg/day) produces significant reductions in body weight, BMI, and waist circumference in obese subjects beyond diet and exercise alone.
Spinach thylakoid supplementation in multiple RCTs produced meaningful body weight loss in overweight women over 3 months by increasing GLP-1-mediated satiety and reducing food cravings. Spinach is also a low-calorie, high-fiber food that contributes to energy deficit patterns.
A systematic review and meta-analysis of 5 RCTs found spirulina supplementation produced a significant mean reduction in body weight of 1.56 kg (95% CI: −1.98 to −1.14) in obese subjects. Effects on BMI and waist circumference are also reported across multiple trials. A 2025 GRADE-assessed meta-analysis confirmed spirulina reduces appetite, improves insulin sensitivity, and exerts anti-inflammatory effects relevant to obesity management.
As a zero-calorie sweetener, stevia can facilitate caloric reduction when substituted for sugar. A 12-week RCT found stevia users maintained weight while controls gained nearly 1 kg. Meta-analyses of low-calorie sweetener RCTs confirm modest but significant body weight reductions versus sugar comparators. Stevia's specific contribution beyond calorie displacement is less established.
As a zero-calorie sugar substitute, steviol glycosides can reduce energy intake when replacing caloric sugar, with broader LNCS meta-analyses supporting modest body weight benefits. Direct evidence for SG-specific effects on BMI from human RCTs shows non-significant trends toward reduction. No SG-specific RCT has used weight as a primary endpoint.
Sulforaphane reduces fat accumulation, inhibits adipogenesis via AMPK pathway activation, and reverses leptin resistance in animal models of obesity. Human RCT data show reductions in triglycerides and oxidized LDL in diabetic patients, and animal studies consistently show improved body composition.
Synephrine, the principal alkaloid from bitter orange (Citrus aurantium), is a β-3 adrenergic receptor agonist that increases thermogenesis and lipolysis without significant cardiovascular effects at normal doses. The NIH ODS and multiple clinical reviews note that bitter orange/synephrine modestly increases resting metabolic rate and may support weight management as part of multi-ingredient formulas.
Meta-analyses of RCTs show modest effects of taurine on body weight and BMI, not reaching statistical significance in most analyses. However, taurine reduces metabolic syndrome components including blood pressure, triglycerides, and fasting glucose. Some evidence suggests taurine may inhibit adipogenesis.
In an 8-week HFD mouse study, THIAA (META060) administration at 0.1% dietary dose significantly reduced body weight gain and fat mass development compared to HFD controls. The mechanism may involve PPARα/γ activation and improved adipocyte metabolism. Human weight data are not available for THIAA specifically.
In a 2026 animal study, threonic acid combined with intermittent fasting produced more pronounced body weight reductions and improvements in energy expenditure than either intervention alone in diet-induced obese mice. The mechanism involves hypothalamic appetite suppression. Evidence is currently preclinical only.
Tocotrienols have been shown in human and animal studies to reduce fat mass and inhibit adipogenesis through modulation of fat cell differentiation and energy sensing pathways. Participants in NAFLD and metabolic syndrome clinical trials who received tocotrienols experienced weight loss as a secondary observation.
A 5-week RCT in men undergoing strength training found those taking 100 mg/day Tongkat Ali had significantly greater lean body mass gains and greater fat loss than placebo. A separate clinical observation noted significant BMI reduction in obese adults over 112 days. Results in already-trained subjects have been mixed, with one 4-week trial in exercise-trained adults finding no body composition difference. Evidence is limited to small trials with concurrent exercise.
The University of Mississippi RCT (n=80, 6–8 weeks, 125 mg twice daily) found a statistically significant minor weight loss (−0.62 kg/m², p=0.012) in participants not on cholesterol medication. Animal studies additionally show PTE activates SIRT1/PGC-1α to enhance thermogenesis and reduce body weight gain in diet-induced obese mice.
A 2021 systematic review of 12 RCTs (749 patients) found Triphala significantly reduced body weight, BMI, and waist circumference in 5 RCTs. A subsequent meta-analysis calculated a weighted mean difference of approximately −2.99 kg. Evidence is specific to overweight and obese populations.
Clinical and mechanistic evidence indicates curcumin can reduce BMI and support weight management through anti-inflammatory and metabolic effects, particularly in obese or metabolically dysregulated individuals. Studies suggest curcumin reduces lipogenesis enzyme activity and increases lipolytic enzyme activity. Effects are modest and best observed alongside lifestyle interventions.
Wasabi extract reduced body weight gain in high-carbohydrate, high-fat diet-fed rats, and wasabi leaf extract inhibited adipose hypertrophy by suppressing PPARγ and stimulating AMPK. The anti-obesity effect of 6-MSITC is mediated through lipid metabolism regulation via PPAR and AMPK pathways. All evidence is preclinical; no human RCTs on body weight have been conducted.
Clinical trials show that substituting watermelon for calorie-equivalent high-fat snacks reduces body weight, BMI, and waist circumference in overweight and obese adults. Watermelon's high water content and fiber provide satiety with low caloric density.
Whole grain wheat intake is consistently associated with lower obesity risk in observational studies, though RCT evidence is mixed. Meta-analyses of clinical trials show whole-grain consumption does not significantly reduce body weight per se, but may reduce body fat percentage, visceral fat, and waist circumference compared to refined grain diets. Mechanisms include increased satiety via fiber bulk and SCFA-mediated GLP-1 stimulation.
Whey protein has the highest thermic effect among protein sources and strongly promotes satiety through GLP-1, GIP, and CCK release, and by stimulating leucine-mediated mTOR signaling for lean mass preservation. Multiple RCTs and meta-analyses demonstrate that whey protein supplementation during caloric restriction significantly reduces body weight, fat mass, and waist circumference while preserving lean mass.
D-xylose supplementation in high-fat diet mouse models significantly suppressed adipogenesis, reduced visceral fat accumulation, downregulated lipogenic gene expression (SREBP-1c, FAS, PPARγ), and improved lipid oxidation markers. A review of natural alternative sweeteners also cited D-xylose's capacity to decrease weight gain and adipose tissue weight. Evidence remains preclinical; no human weight-management RCTs have been published.
A 12-week double-blind RCT found yerba mate supplementation significantly reduced body fat mass, percent body fat, and waist-to-hip ratio compared to placebo in obese individuals. Mechanisms include pancreatic lipase inhibition, increased energy expenditure, and enhanced fat oxidation during exercise.
Yohimbine has been tested in clinical trials for fat loss, with mixed results. A well-cited RCT in elite soccer players showed a significant reduction in body fat percentage versus placebo over 21 days. However, other trials using higher doses in overweight men found no significant fat loss advantage. Overall, evidence suggests modest effects at low doses in conjunction with exercise and caloric restriction, particularly in a fasted state.
Ajwain is traditionally used in Ayurveda as a digestive stimulant that aids metabolism and is associated with weight management. Laxative and digestive enzyme-stimulating properties provide indirect mechanistic support. No human RCTs measuring body weight or BMI as primary outcomes have been published.
Animal studies show that A. bisporus extract (ABE) inhibits pancreatic lipase, reducing dietary lipid absorption and body weight gain in high-fat diet mice. A separate study found reduced food intake and lower body weight in mushroom-fed animal groups. No controlled human RCTs for weight outcomes have been published.
Commiphora mukul (guggul) is described in Ayurvedic texts (Sushruta Samhita) as a treatment for obesity (medoroga). Human clinical trials have not demonstrated significant weight loss benefit compared to placebo; evidence remains traditional/preclinical.
Corn silk has traditional documented use for obesity management and weight loss across multiple cultures. Preclinical studies show corn silk extract reduces adipogenesis and HFD-induced weight gain in mice. No human RCTs have specifically evaluated corn silk for weight management.
Corn silk has traditionally been included in weight management formulas due to its diuretic action reducing water weight. Animal studies show reductions in body mass index and body weight in obese models treated with corn silk extract. No human RCTs for weight or adiposity have been published.
Dandelion (Taraxacum officinale) has been used in traditional European and Chinese herbal medicine as a diuretic and mild digestive bitter to support weight management, particularly water weight reduction. Modern research suggests it inhibits pancreatic lipase and may reduce postprandial fat absorption, with some evidence for modest weight-related effects.
E. littorale is documented in Siddha medicine for obesity, and Ayurvedic texts identify its main site of action as medodhatu (adipose tissue), with anti-obesity properties noted. Preclinical anti-obesity data exist, and swertiamarin supplementation has been shown to prevent obesity-related chronic inflammation in high-fat diet mice. Clinical weight management trials are lacking.
Guggul has been used traditionally in Ayurveda for obesity and excess body weight, attributed to its ability to enhance metabolic fire (agni) and reduce Ama. Limited clinical data from small double-blind trials show modest results, and a well-designed pilot trial failed to show significant weight-loss benefit compared to placebo.
Gymnema sylvestre has been used in Ayurvedic medicine for over 2,000 years to reduce sugar cravings and support healthy glucose metabolism, traditionally called 'gurmar' (sugar destroyer). Its gymnemic acids suppress sweet taste receptors and inhibit glucose absorption, which may reduce caloric intake from carbohydrates and support weight management in the context of blood sugar control.
Gymnema Sylvestre ('gurmar' or 'sugar destroyer') is a cornerstone Ayurvedic herb for metabolic and weight management support. Its gymnemic acids block sweet taste receptors and inhibit intestinal glucose absorption, reducing carbohydrate-driven caloric intake. Traditional and emerging clinical evidence supports its role in healthy weight via blood sugar regulation.
Hoodia gordonii is a succulent used traditionally by the San people of southern Africa as an appetite suppressant during long hunts. The NIH ODS documents this traditional use and notes animal studies show reduced food intake; however, published human clinical trial evidence for weight loss is limited and mixed.
Wheatgrass is promoted in naturopathic traditions for weight management, attributed to its low-calorie nutrient density, enzyme content supporting metabolism, and fiber content promoting satiety. No human RCT has assessed wheatgrass as a weight-loss intervention.
Go back